+ +

•  

   

     Western blot analysis of ZNF217 expression in Caco2 cell lysate.    

  
  

The ZNF217 antibody is a crucial tool in studying the ZNF217 protein, encoded by the ZNF217 gene, which belongs to the Krüppel-associated box (KRAB) zinc finger protein family. ZNF217 functions as a transcriptional regulator and is implicated in oncogenesis, primarily due to its role in promoting cancer cell proliferation, metastasis, and resistance to therapy. It interacts with chromatin-modifying complexes (e.g., Polycomb repressive complexes) to repress tumor suppressor genes and drive epithelial-mesenchymal transition (EMT), a key process in cancer progression. Overexpression of ZNF217 is observed in various cancers, including breast, ovarian, and colorectal cancers, correlating with poor prognosis and therapeutic resistance.

The ZNF217 antibody enables detection and quantification of ZNF217 protein levels in research applications such as Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF). It is widely used to investigate ZNF217's mechanistic roles in cancer biology, particularly its involvement in epigenetic regulation, DNA damage response, and stem cell-like properties in tumors. Commercially available ZNF217 antibodies are typically raised against specific epitopes (e.g., human ZNF217 amino acid sequences) and validated for specificity using knockout cell lines or siRNA-mediated knockdown. Researchers also employ these antibodies to explore ZNF217's potential as a biomarker or therapeutic target, emphasizing its relevance in precision oncology. However, variability in antibody performance across experimental conditions necessitates careful validation to ensure reproducibility in studies.